1
|
Nasr Z, Iravani M, Mokhtari J. Measurement of Isfahan heavy water zero-power reactor kinetic parameters using advanced pulsed neutron source method in a near critical state. Appl Radiat Isot 2024; 204:111126. [PMID: 38039828 DOI: 10.1016/j.apradiso.2023.111126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 11/23/2023] [Accepted: 11/23/2023] [Indexed: 12/03/2023]
Abstract
The pulsed neutron source (PNS) technique was used to determine the prompt neutron decay constant for two different lattice pitches in the HWZPR heavy water zero power reactor. The results were compared to the variance-to-mean ratio (VTM) method. The neutron mean generation time was also calculated for both pitches, and the results were compared to previous Monte Carlo calculations. The findings of this research can be used as a benchmark nuclear codes to validate kinetic parameters.
Collapse
Affiliation(s)
- Z Nasr
- Reactor and Nuclear Safety Research School, Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran, Isfahan, Iran
| | - M Iravani
- Reactor and Nuclear Safety Research School, Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran, Isfahan, Iran
| | - J Mokhtari
- Reactor and Nuclear Safety Research School, Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran, Isfahan, Iran.
| |
Collapse
|
2
|
Shojaei S, Aznab M, Rahimi A, Ahmadi SM, Eslampia K, Golpazir A, Iravani M. Evaluation of the Role of Tumor-Infiltrating Lymphocytes and CD8 + Cytotoxic Lymphocytes in the Survival of Patients with Breast Cancer. Int J Hematol Oncol Stem Cell Res 2023; 17:9-17. [PMID: 37638284 PMCID: PMC10448926 DOI: 10.18502/ijhoscr.v17i1.11708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 05/09/2021] [Indexed: 08/29/2023] Open
Abstract
Background: This study aimed to evaluate the significance of tumor-infiltrating lymphocyte (TIL) and the number of CD8+ T cells in breast cancer and their relationship with the other clinicopathological factors, and overall survival (OS) was investigated. Materials and Methods: The studied samples were breast cancer patients (2005-2017) referring to the medical oncology departments for treatment. Pathologic samples of breast cancer patients were evaluated in terms of TIL and positive immunohistochemical staining for CD8 cytotoxic cells. Results: 299 patients were entered into the study, three were male and 296 female. Their mean follow-up period was 61 months. Statistical findings indicated that lymph involvement is more accompanied by low TIL within the tumor (0.011). Correlations were observed between the estrogen, progesterone receptors, P53 state, and TIL, which were significant by P-value<0.049, P-value=0.024, P-value =0.002, respectively. With any Ki67 value, the number of patients with less than 30% TIL was more considerable than the other two groups with lymphocyte cut-off of 30-50% and more than 50%. Comparison of the OS of patients with positive and negative CD8 cytotoxic lymphocytes in 45 patients with lymphocyte infiltration of equal or more than 40% showed that the OS results were in favor of patients with CD8+ cytotoxic lymphocyte (0.022). Out of 299 patients, 17 died. Conclusion: Our findings showed that in cases of CD8+ cytotoxic lymphocytes in tumors, the OS of the patients will be enhanced which can act as an independent factor.
Collapse
Affiliation(s)
| | - Mozaffar Aznab
- Department of Internal Medicine, Talaghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | | | - Seyed Mojtaba Ahmadi
- Department of Clinical Psychology School of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran
| | | | - Arash Golpazir
- Department of Surgery, Cancer Surgery, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | | |
Collapse
|
3
|
Fitzpatrick A, Iravani M, Okines A, Harries M, Tutt A, Isacke C. 87MO Assessing tumour fraction of CSF cfDNA improves diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis (BCLM). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Nevisi F, Yaghmaie M, Pashaiefar H, Alimoghaddam K, Iravani M, Javadi G, Ghavamzadeh A. Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study. ibj 2020. [PMID: 31454863 PMCID: PMC6900480 DOI: 10.29252/ibj.24.1.47] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Background: The analysis of the gene copy number alterations in tumor samples are increasingly used for diagnostic and prognostic purposes in patients with GC. However, these procedures are not always applicable due to their invasive nature. In this study, we have analyzed the copy number alterations of five genes (HER2, MDM2, c-MYC, c-MET, and TP53) with a fixed relevance for GC in the CTC of GC patients, and, accordingly, as a potential approach, evaluated their usage to complete primary tumor biopsy. Methods: We analyzed the status of the copy number alterations of the selected genes in CTC and matched biopsy tissues from 37 GC patients using FISH. Results: HER2 amplification was observed in 2 (5.41%) samples. HER2 gene status in CTC showed a strong agreement with its status in 36 out of 37 patients’ matched tissue samples (correlation: 97.29%; Kappa: 0.65; p < 0.001). MDM2 amplification was found only in 1 (2.70%) sample; however, the amplification of this gene was not detectable in the CTC isolated from this patient. c-MYC amplification was observed in 3 (8.11%) samples, and the status of its amplification in the CTC indicated a complete agreement with its status in the matched tissue samples (correlation: 100%; Kappa: 1.0). Conclusion: Our work suggests that the amplification of HER2 and c-MYC is in concordance with the CTC and achieved biopsies, and, consequently, CTC may act as a non-invasive alternative for recording the amplification of these genes among GC patients.
Collapse
Affiliation(s)
- Fatemeh Nevisi
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Marjan Yaghmaie
- Hematology, Oncology and Stem cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Corresponding Author: Marjan Yaghmaie , Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; Fax: (+98-21) 88224140; E-mail:
| | - Hossein Pashaiefar
- Hematology, Oncology and Stem cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Kamran Alimoghaddam
- Hematology, Oncology and Stem cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Gholamreza Javadi
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Ardeshir Ghavamzadeh
- Hematology, Oncology and Stem cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
Abbasian MH, Ansarinejad N, Abbasi B, Iravani M, Ramim T, Hamedi F, Ardekani AM. The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. Avicenna J Med Biotechnol 2020; 12:157-164. [PMID: 32695278 PMCID: PMC7368113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND The fluoropyrimidine drug 5-Fluorouracil (5-FU) and the prodrug capecitabine have been extensively used for treatment of many types of cancer including colorectal, gastric, head and neck. Approximately, 10 to 25% of patients suffer from severe fluoropyrimidine-induced toxicity. This may lead to dose reduction and treatment discontinuation. Pharmacogenetics research could be useful for the identification of predictive markers in chemotherapy treatment. The aim of the study was to investigate the role of five genetic polymorphisms within two genes (DPYD, TYMS) in toxicity and efficacy of fluoropyrimidine-based chemotherapy. METHODS Total genomic DNA was extracted from 83 cancer patients treated with fluoropyrimidine-based chemotherapy. In this study, three polymorphisms were genotyped in dihydropyrimidine dehydrogenase gene c.1905+1 G>A (DPYD*2A; rs3918290), c.1679 T>G (I560S; DPYD*13; rs55886062), and c.2846A>T (D949V; rs67376798) and two polymorphisms, besides the Variable Number of Tandem Repeat (VNTR) polymorphism and 6-bp insertion/deletion polymorphism in thymidylate synthase gene. The analysis of polymorphisms for rs3918290, rs55886062, rs67376798 and 6-bp insertion/deletion in TYMS was done by Polymerase Chain Reaction-restriction Fragment Length Polymorphism (PCRRFLP) TYMS VNTR analysis. 5-FU-related toxicities such as anemia, febrile neutropenia, neurotoxicity, vomiting, nausea, and mucositis were evaluated according to NCI-CTC criteria version 4.0. T-test and chi-square were used and p-values less than 0.05 were considered statistically significant. RESULTS DPYD gene polymorphisms were not observed in this study. The frequency of the TYMS +6 bp allele was 40.35% and the -6 bp allele was 59.65% in this study. The frequency of VNTR 2R allele was 48.75% and 3R allele was 51.15%. Toxicity grade II diarrhea, mucositis, nausea, vomiting, and neurotoxicity was 2.2, 24.1, 15.7, 6, and 51.8%, respectively. Thymidylate synthase ins/del polymorphisms were associated with increased grade III neurotoxicity (p=0.02). Furthermore, anemia grade III was significantly associated with 2R/2R genotype (0.009). CONCLUSION Thymidylate synthase gene polymorphisms may play a key role in fluoropyrimidne -based chemotherapy. Although rare DPYD polymorphisms were not observed in our study, according to large population studies, DPYD gene polymorphisms could be used as a predictive biomarker for patient treatments.
Collapse
Affiliation(s)
- Mohammad Hadi Abbasian
- Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
| | - Nafiseh Ansarinejad
- Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran,Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran
| | - Bahareh Abbasi
- Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran,Department of Medical Genetic, Medical Biotechnology Ins., National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
| | - Masoud Iravani
- Tehran Gastroenterology and Hepatology Center, Tehran, Iran
| | - Tayeb Ramim
- Department of Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Fahime Hamedi
- Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
| | - Ali M. Ardekani
- Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran,Corresponding author: Ali M. Ardekani, Ph.D., Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran, Tel: +98 21 44787301, Fax: +98 21 44787399, E-mail:
| |
Collapse
|
6
|
Olsen C, Liu G, Iravani M, Nguyen S, Khourdadjian K, Turner D, Waxman K, Selam JL, Charles M. Long-Term Safety and Efficacy of Programmable Implantable Insulin Delivery Systems. Int J Artif Organs 2018. [DOI: 10.1177/039139889301601211] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives Since only short-term studies of continuous intraperitoneal insulin infusion (CIPII) therapy using implantable programmable insulin delivery systems have been performed to show this method of diabetes therapy to be safe and efficacious, we have performed long-term studies to assess its safety and efficacy. Research design and methods For 78 patient-years of follow-up, we have longitudinally studied the incidence of diabetic ketoacidosis and severe hypoglycemia in 25 type 1 diabetic patients treated with CIPII. We also compared, cross-sectionally, the long-term safety and efficacy of CIPII to intensive subcutaneous insulin therapy using intermittent injections or continuous subcutaneous insulin infusion. Finally, we examined the relationship between glycated hemoglobin levels and the standard deviation of daily blood glucose excursion. Results Cross-sectional analysis revealed similar degrees of metabolic control accompanied by significantly decreased rates of both ketoacidosis (0.013 events/patient/year) and severe hypoglycemia (0.05 events/patient/year) during CIPII compared to intermittent injections and continuous subcutaneous insulin infusion therapy. A four-fold decrease in the rate of severe hypoglycemia was observed during longitudinal comparison of pre- and post-implantation complication rates. A relationship was also shown between decreased levels of mean glycated hemoglobin and the standard deviation of blood glucose excursions during CIPII therapy. Conclusions Our data demonstrate that long-term therapy with CIPII is as effective as other methods in achieving near-normal levels of glycated hemoglobin, which in CIPII is associated with a decreased standard deviation of blood glucose excursions. Further, CIPII using implantable programmable insulin delivery systems is the safest method described for intensive insulin therapy in home blood glucose monitoring type 1 diabetic patients.
Collapse
Affiliation(s)
- C.L. Olsen
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - G. Liu
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - M. Iravani
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - S. Nguyen
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - K. Khourdadjian
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - D.S. Turner
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - K. Waxman
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - J-L. Selam
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| | - M.A. Charles
- Diabetes Research Program, Department of Medicine University of California, Irvine, California - USA
| |
Collapse
|
7
|
Radfar M, Faghihi T, Hadjibabaie M, Ebrahimi F, Qorbani M, Iravani M, Ghavamzadeh A. Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation. Endocr Res 2015; 40:20-4. [PMID: 24833082 DOI: 10.3109/07435800.2014.914037] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
New onset diabetes mellitus is frequently observed following hematopoietic stem cell transplantation (HSCT) and is associated with adverse transplantation outcomes. However, the outcomes of patients with preexisting diabetes mellitus undergoing HSCT are largely unknown. We aimed to explore the impact of preexisting diabetes on transplantation outcomes in HSCT. In a retrospective study, medical charts of 34 HSCT recipients with diabetes mellitus undergoing allogeneic or autologous transplantation were reviewed and compared with 71 HSCT recipients without diabetes. Primary outcome was overall survival. Secondary outcomes included hematopoietic recovery, length of hospital stay, febrile neutropenia, acute and chronic graft-versus-host disease (GVHD), primary disease recurrence, and non-relapse mortality (NRM). On univariate analysis, there was no difference in transplantation outcomes in recipients with diabetes compared with recipients without diabetes. However, after adjusting for potential covariates, multivariate analysis demonstrated that having diabetes before HSCT significantly predicted outcome and decreased overall survival (hazard ratio 0.51, 95% confidence interval: 0.27-0.97, p value: 0.04). This study suggests that patients with diabetes mellitus undergoing allogeneic or autologous HSCT may have inferior survival rates and warrant further attention.
Collapse
Affiliation(s)
- Mania Radfar
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences , Tehran , Iran
| | | | | | | | | | | | | |
Collapse
|
8
|
Van Weverwijk A, Ashenden M, Murugaesu N, Iravani M, Isacke C. 369: An in vivo shRNA screen to identify novel drivers and therapeutic targets of breast cancer metastasis. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50329-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi S, Bahar B, Iravani M, Ghaffari F, Jalili M, Jalali A. Autologous and Allogenic Stem Cell Transplantation Results in Multiple Myeloma Patients – Single Center Study. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Ghavamzadeh A, Hoghooghi M, Jahani M, Alimoghaddam K, Mousavi S, Bahar B, Iravani M, Jalili M, Jalali A. Effect of Pre-Transplant Chemotherapy Before Human Leukocyte Antigen Identical Sibling Transplantation for Acute Myelogenous Leukemia in First Complete Remission. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Jenner P, Iravani M, McCreary A. 2.12.1 STRIATAL PLASTICITY IN PARKINSON'S DISEASE AND L-DOPA INDUCED DYSKINESIA. Parkinsonism Relat Disord 2012. [DOI: 10.1016/s1353-8020(11)70412-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Isacke C, Murugaesu N, Iravani M, Johnson D, Ashworth A, Lord C. 122 INVITED Tumour – Stroma Interactions in Breast Cancer Metastasis. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70337-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Hamidieh AA, Alimoghaddam K, Jahani M, Mousavi SA, Iravani M, Bahar B, Jalili M, Jalali A, Behfar M, Ghavamzadeh A. Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients. Hematol Oncol Stem Cell Ther 2011; 4:109-15. [DOI: 10.5144/1658-3876.2011.109] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
14
|
Mansouri A, Hadjibabaie M, Iravani M, Shamshiri AR, Hayatshahi A, Javadi MR, Khoee SH, Alimoghaddam K, Ghavamzadeh A. The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. Hematol Oncol 2011; 30:22-6. [DOI: 10.1002/hon.999] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2011] [Accepted: 04/27/2011] [Indexed: 11/12/2022]
Affiliation(s)
- Ava Mansouri
- Faculty of Pharmacy; Department of Clinical Pharmacy; Tehran University of Medical Sciences; Tehran; Iran
| | - Molouk Hadjibabaie
- Faculty of Pharmacy; Department of Clinical Pharmacy; Tehran University of Medical Sciences; Tehran; Iran
| | - Masoud Iravani
- Hematology-Oncology and SCT Research Center; Department of Hematology-Oncology, Shariati Hospital; Tehran University of Medical Sciences; Tehran; Iran
| | - Ahmad Reza Shamshiri
- Department of Epidemiology and Biostatistics; School of Public Health; Tehran University of Medical Sciences; Tehran; Iran
| | - Alireza Hayatshahi
- Faculty of Pharmacy; Department of Clinical Pharmacy; Tehran University of Medical Sciences; Tehran; Iran
| | - Mohammad Reza Javadi
- Faculty of Pharmacy; Department of Clinical Pharmacy; Tehran University of Medical Sciences; Tehran; Iran
| | - Seid Hamid Khoee
- Faculty of Pharmacy; Department of Clinical Pharmacy; Tehran University of Medical Sciences; Tehran; Iran
| | - Kamran Alimoghaddam
- Hematology-Oncology and SCT Research Center; Department of Hematology-Oncology, Shariati Hospital; Tehran University of Medical Sciences; Tehran; Iran
| | - Ardeshir Ghavamzadeh
- Hematology-Oncology and SCT Research Center; Department of Hematology-Oncology, Shariati Hospital; Tehran University of Medical Sciences; Tehran; Iran
| |
Collapse
|
15
|
Yakimchuk K, Iravani M, Hasni MS, Rhönnstad P, Nilsson S, Jondal M, Okret S. Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo. Leukemia 2011; 25:1103-10. [PMID: 21502954 DOI: 10.1038/leu.2011.68] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Estrogen receptor β (ERβ) is expressed in immune cells and studies have suggested an antiproliferative function of ERβ. We detected ERβ expression in murine T- and human B-cell lymphoma cell lines and analyzed the effects of estradiol and selective ERβ agonists on lymphoma growth in culture and in vivo. Treating the cells with estradiol had minor effects on cell growth, whereas the selective ERβ agonists diarylpropionitrile (DPN) and KB9520 showed a strong antiproliferative effect. When grafting mice with murine T-cell lymphoma cells, male mice developed larger tumors compared with female mice, a difference that was abolished following ovariectomy, showing estrogen-dependent growth in vivo. To investigate whether lymphoma growth may be inhibited in vivo by ERβ agonist treatment, mice grafted with murine lymphoma cells were treated with DPN or KB9520. Both ERβ-selective agonists strongly inhibited lymphoma growth. The reduced tumor size seen following either DPN or KB9520 treatment was due to reduced proliferation and increased apoptosis. Our results show an ERβ ligand-dependent antiproliferative effect of lymphoma cells expressing endogenous ERβ and that lymphoma cell growth in vivo can efficiently be inhibited by ERβ agonists. This suggests that ERβ agonists may be useful in the treatment of lymphomas.
Collapse
Affiliation(s)
- K Yakimchuk
- Department of Biosciences and Nutrition, Karolinska Institutet, Novum, Huddinge, Sweden
| | | | | | | | | | | | | |
Collapse
|
16
|
Ghavamzadeh A, Alimoghaddam K, Hamidieh A, Jalili M, Bahar B, Iravani M, Mousavi S, Jahani M. Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Severe Aplastic Anemia. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Alimoghaddam K, Jahani M, Mousavi S, Bahar B, Iravani M, Hamidieh A, Jorjani H, Jalali A, Ghavamzadeh A. Hematopoietic Stem Cell Transplantation in Lymphoma Patients: the Iranian Experience. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.300] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Hadjibabaie M, Rahimian S, Jahangard-Rafsanjani Z, Amini M, Alimoghaddam K, Iravani M, Ghavamzadeh A, Sadrai S. Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. Daru 2011; 19:216-23. [PMID: 22615660 PMCID: PMC3232103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2011] [Revised: 06/20/2011] [Accepted: 06/22/2011] [Indexed: 10/27/2022] Open
Abstract
BACKGROUND AND THE PURPOSE OF THE STUDY Many factors have been reported that contribute to the wide intra- and inter-patient variability of Busulfan (Bu) disposition. The purpose of this study was to develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics (PK) of Bu in Iranian adult patients who received oral high-dose as a conditioning regimen before Hematopoietic Stem Cell Transplantation (HSCT). METHODS A population PK analysis was performed in 30 patients who received an oral Bu and cyclophosphamide regimen before HSCT. Bu was given orally according to the protocol of the institution. In order to prevent seizures caused by Bu, phenytoin was administered orally one hour before each dose of Bu.A total of 180 blood samples were analyzed by HPLC and PK parameters were estimated by the non-linear mixed effect model by MONOLIX 3.1 program. A one-compartment model with an additive error model was used to describe the concentration-time profile of Bu. RESULTS Patients' disease and weight was found to be the determinant factors for clearance (CL) and the volume of distribution (Vd) according to Monolix analysis. The covariate entered in final model followed by these equations:[Formula: see text][Formula: see text] In this limited study, the age (15-43 years) had no significant effect. For a patient weighting 60 kg, the typical CL and Vd were estimated to be 13.4 l/hr and 42.6 L, respectively. The interindividual variability of CL and Vd were 13.6 and 6.3%, respectively. There was no significant metabolic induction in these four days as is evident by comparing the trough levels of Bu. However it should be mentioned that, one tailed t-test p-values of the days of two and three, two and four and three and four were 0.083, 0.069 and 0.388, respectively. MAJOR CONCLUSIONS Results of this study showed that the type of disease was a determinant of CL and the weight of patient was a determinant of Vd for Bu population PK parameters. A reliable PK parameters and Css, estimated from only one plasma concentrations (5 hrs after the first dose), were validated. Since these methods require few sampling and are easy to be used, the limited sampling methods might be advantageous in the routine clinical practice.
Collapse
Affiliation(s)
| | | | | | - M. Amini
- Department of Medicinal Chemistry, Faculty of Pharmacy
| | - K. Alimoghaddam
- Faculty of Medicine, Hematology-Oncology and Bone Mass Translplantation (BMT) Research Center
| | - M. Iravani
- Faculty of Medicine, Hematology-Oncology and Bone Mass Translplantation (BMT) Research Center
| | - A. Ghavamzadeh
- Faculty of Medicine, Hematology-Oncology and Bone Mass Translplantation (BMT) Research Center
| | - S. Sadrai
- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
19
|
Ghavamzadeh A, Alimoghaddam K, Ghaffari S, Rostami S, Jahani M, Iravani M, Mousavi S, Jalili M, Alizadeh N, Khodabandeh A. Results of new cases of APL treatment by arsenic trioxide and long-term follow-up: Is it time for using arsenic trioxide in first-line treatment? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Tan DS, Iravani M, Lambros MB, Mackay A, Gourley C, Williams A, McCluggage WG, Ashworth A, Kaye SB, Reis- Filho JS. Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Ghavamzadeh A, Alimogaddam K, Jahani M, Mousavi S, Iravani M, Bahar B, Khodabandeh A, Khatami F, Jalali A. Hematopoietic stem cell transplantation in Iran: 1991 to 2008. Hematol Oncol Stem Cell Ther 2010; 1:231-8. [PMID: 20058479 DOI: 10.1016/s1658-3876(08)50010-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
Since 1991, 2042 first hematopoietic stem cell transplants (HSCT) have been performed at the Hematology-Oncology and Stem Cell Transplantation Research Center at Tehran University of Medical Sciences. Acute myelogenous leukemia (548 patients), thalassemia major (335 patients) and acute lymphoblastic leukemia (275 patients) have been the most common transplanted disorders. There were 1418 cases that received allogeneic HSCT and 624 cases that have received autologous HSCT. The numbers of allogeneic and autologous HSCT have increased, but the allogeneic to autologous ratio has remained constant. The first peripheral blood hematopoietic stem cell transplantation was performed in 1996; since then, 1671 have been done. The donor types for 1418 allogeneic first HSCT were 1367 (96.4%) human leukocyte antigen (HLA) matched-identical siblings, 29 (2%) HLA-mismatched sibling/other relative, 13 (0.9%) syngeneic twins, 5 (0.4%) HLA-matched other relatives and 4 (0.3%) unrelated. The first cord blood hematopoietic stem cell transplantation was performed in 1998 and since then there have been 14 patients that have obtained cord blood transplantations. Recently, new methods have been used like donor lymphocyte infusion (DLI) and cellular therapy. There were 111 patients with cellular therapy for post-myocardial infarction, cirrhosis, thalassemia major, multiple sclerosis, head of femur necrosis and renal cell carcinoma.
Collapse
Affiliation(s)
- Ardeshir Ghavamzadeh
- Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Dr. Shariati Hospital, Tehran, Iran
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
An Q, Jones L, Tapper W, Chelala C, Iravani M, MacKay A, Hammond V, Durcan L, Gerty S, Ferguson A, Strefford J, Peock S, Reis-Filho J, Easton D, Ashworth A, Eccles D. A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations. Breast Cancer Res 2010. [PMCID: PMC2875593 DOI: 10.1186/bcr2528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
23
|
Iravani M, Tavakoli E, Babaie MH, Ashouri A, Khatami F, Ghavamzadeh A. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. EXP CLIN TRANSPLANT 2010; 8:66-73. [PMID: 20199374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
OBJECTIVES This study aimed to compare outcome of bone marrow transplant with peripheral blood stem cell transplant in class 3 thalassemic patients. MATERIALS AND METHODS Respectively, 32 and 20 class 3 thalassemic patients received bone marrow transplant and peripheral blood stem cell transplant from human leukocyte antigen identical sibling donors. Conditioning regimen consisted of busulfan (16 mg/kg) and cyclophosphamide (160 mg/kg) followed by cyclosporine and methotrexate as graft-versus-host disease prophylaxes. RESULTS Median time to absolute neutrophil count was significantly shorter in the peripheral blood stem cell transplant group (12 vs 23 days); however, there was no significant difference regarding platelet recovery between the 2 groups (20 vs 28 days). Acute graft-versus-host disease occurred in 47% of patients. Chronic graft-versus-host disease developed in 28% of patients which was significantly higher in the peripheral blood stem cell transplant group (P = .06). During 50 months follow-up, thalassemia recurrence, overall survival, and thalassemia-free survival were 17%, 80%, and 65%, respectively, and there were no significant differences between the 2 groups. CONCLUSIONS These results showed that stem cell transplant is an effective treatment in class 3 thalassemic patients with the outcome relatively similar to bone marrow transplant. Although engraftment time is shorter in peripheral blood stem cell transplant method, it is associated with higher rate of chronic graft-versus-host disease.
Collapse
Affiliation(s)
- Masoud Iravani
- Tehran University of Medical Sciences, Department of Hematology, Tehran, Iran
| | | | | | | | | | | |
Collapse
|
24
|
Ghavamzadeh A, Hamidieh A, Jahani M, Alimoghaddam K, Iravani M, Mousavi S, Bahar B, Khodabandeh A, Jalili M. HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation In 36 Pediatric Patients With Severe Acquired Aplastic Anaemia. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Eccles D, An Q, Jones L, Tapper W, Chelala C, Iravani M, McKay A, Hammond V, Durcan L, Gerty S, Strefford J, Ferguson A, Peock S, Reis-Filho J, Easton D, Ashworth A. A Novel Tumour-Based Test To Identify Breast Cancer Due to BRCA1 and BRCA2 Mutations. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Family history and young onset are the usual indicators of an underlying genetic predisposition to breast cancer development. BRCA1 associated breast tumours are more likely to be ER negative and express “basal” markers, however most patients with ER negative/ basal marker positive breast cancers (especially young onset) do not have inherited BRCA1 mutations. BRCA1 and BRCA2 gene carriers may have novel treatment options available and may need to consider future cancer prevention strategies. Genetic counselling and germline mutation analysis remains a relatively expensive option that is not appropriate for most breast cancer patients.Aim: To design a sensitive and specific pathology based predictor that would improve identification of BRCA1 and 2 gene carriers.Method: We assembled a training panel of breast cancer tumour blocks from 67 BRCA1, 71 BRCA2 associated and 105 sporadic young onset cases (≤ 40 years at diagnosis). All gene carriers were diagnosed before 50 years and were matched to sporadic cases for ER status. Tissue micro arrays (TMAs) were assembled and subjected to immunohistochemical analysis with a panel of 18 antibodies. DNA was extracted from micro dissected tumour tissue and matched patient lymphocytes and subjected to high resolution tiling path microarray-based Comparative Genomic Hybridisation (aCGH). Using robust statistical approaches, regions significantly differentially lost, gained or amplified in BRCA1, BRCA2 and controls were identified. Probes for chromogenic in situ hybridisation (CISH) for amplified regions were generated.Results: Two differentially amplified clones in BRCA1 cases designated P1 at 3q25.31 and P2 at 3q25.2 and one in BRCA2 cases, P3 at 20q13.13, were identified and amplifications validated in the training set using CISH. Logistic regression analysis of the panel comprising CISH and IHC markers was used to develop the best predictor. The best predictor for BRCA1 gene carriers was a combination of P1, ER and HER2. This combination outperformed all combinations of immunohistochemical markers, including ER and basal markers; the Positive Predictive Value (PPV) was 87.5% and NPV 92% giving a Receiver Operator Characteristic (ROC) curve with an AUC of 0.92 (CI 0.88-0.97). The BRCA2 signature panel is currently being evaluated. These BRCA1 and BRCA2 predictor panels are being validated in a new set of TMAs comprising 223 tumours from the POSH study1.Conclusion: This tumour based predictor for BRCA1 and BRCA2 carriers may prove useful to identify gene carriers at low a priori chance of having a mutation, to direct BRCA1/2 targeted treatment approaches and to identify familial non BRCA1/2 cases that may be suitable for new gene discovery studies.1. Eccles D et al. BMC Cancer 2007; 7(1):160.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5032.
Collapse
Affiliation(s)
- D. Eccles
- 1University of Southampton, Hampshire, United Kingdom
| | - Q. An
- 1University of Southampton, Hampshire, United Kingdom
| | - L. Jones
- 2Queen Mary University London, United Kingdom
| | - W. Tapper
- 1University of Southampton, Hampshire, United Kingdom
| | - C. Chelala
- 2Queen Mary University London, United Kingdom
| | - M. Iravani
- 3The Breakthrough Breast Cancer Research Centre, United Kingdom
| | - A. McKay
- 3The Breakthrough Breast Cancer Research Centre, United Kingdom
| | - V. Hammond
- 1University of Southampton, Hampshire, United Kingdom
| | - L. Durcan
- 1University of Southampton, Hampshire, United Kingdom
| | - S. Gerty
- 1University of Southampton, Hampshire, United Kingdom
| | - J. Strefford
- 1University of Southampton, Hampshire, United Kingdom
| | - A. Ferguson
- 2Queen Mary University London, United Kingdom
| | - S. Peock
- 4University of Cambridge, United Kingdom
| | - J. Reis-Filho
- 3The Breakthrough Breast Cancer Research Centre, United Kingdom
| | - D. Easton
- 4University of Cambridge, United Kingdom
| | - A. Ashworth
- 3The Breakthrough Breast Cancer Research Centre, United Kingdom
| |
Collapse
|
26
|
Faghihi T, Iravani M, Shamshiri AR, Hadjibabaie M, Mousavi SA, Alimoghaddam K, Ghavamzadeh A. Serum electrolyte changes at engraftment time in patients undergoing allogeneichematopoietic stem cell transplantation. Ann Transplant 2009; 14:51-57. [PMID: 19644160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Accepted: 07/01/2009] [Indexed: 05/28/2023] Open
Abstract
BACKGROUND Metabolic abnormalities have been reported in patients undergoing hematopoietic stem cell transplantation (HSCT). Potential causes, risk factors and outcomes of electrolyte imbalances have thoroughly been investigated. On HSCT recipients, multiple pathophysiologic contributors are inflicting electrolyte abnormalities, with special attention being paid to engraftment per se as an important contributor. Engraftment contribution to electrolyte imbalances has been reported for hypophosphatemia and for other electrolyte abnormalities in autologous setting. However in the allogeneic setting serum electrolyte level changes and the timing of any probable abnormality are unknown. MATERIAL AND METHODS We performed a retrospective study in order to evaluate the pattern of phosphorous, magnesium, potassium and uric acid serum changes, timing of any probable abnormality and their possible association with WBC and platelet engraftment in 65 allogeneic HCT recipients from day -9 to +32 after transplantation. Besides we assessed frequency and severity of the abnormalities. RESULTS We observed a declining pattern of electrolyte concentrations with nadirs antedating WBC and platelet engrafments. Phosphorous and potassium serum changes were correlated with natural logarithm of WBC and platelet level changes. Observed overall incidence of hypophosphatemia (9.2%) and hypomagnesemia (3%) was lower than those previously reported. CONCLUSION Abnormalities found reflect a combination of pathophysiologic mechanisms. Occurrence of electrolyte nadirs antedating engraftment confirms increased consumption by rapidly replicating cells as a contributor in allogeneic setting and specifies a susceptible period requiring intensive monitoring. Considering high risk patients and managing various organ system complications lower incidence of some electrolyte abnormalities may be observed.
Collapse
Affiliation(s)
- Toktam Faghihi
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | |
Collapse
|
27
|
Hadjibabaie M, Iravani M, Shamshiri AR, Zaker Z, Mousavi A, Alimoghaddam K, Bahar B, Kalantar E, Ghavamzadeh A. The prevalence of low selenium levels in adult patients undergoing bone marrow transplantation: a brief communication. Nutr Cancer 2009; 60:837-9. [PMID: 19005983 DOI: 10.1080/01635580802196107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Selenium (Se) is an essential trace element, and its deficiency is considered to be important in various types of cancer. There are just a few data regarding this issue among adult patients with hematological malignancy. Serum Se levels were determined in 22 adult patients candidates for bone marrow transplantation (BMT) in Iran. The mean serum Se levels before BMT was 19.91 microg/l (from 12.00 to 62.00 microg/l), and almost all the patients had low Se serum levels (normal serum Se level: 46-143 microg/l). The level of Se 20 days after BMT was 22.53 microg/l, which did not show any significant changes. Most of the patients did not suffer from malnutrition, as they had mostly normal albumin levels. Even though the results of this study showed that Se deficiency is common among our hematological malignant patients, it can not be concluded that these low Se levels are causally related to cancers for which BMT is undertaken. Further studies are needed to evaluate the Se levels at diagnosis before treatment effects.
Collapse
Affiliation(s)
- Molouk Hadjibabaie
- Faculty of Pharmacy, Medical Sciences, University of Tehran, Tehran, Iran
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Marchiò C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, Schmitt FC, Bussolati G, Ellis LO, Ashworth A, Sapino A, Reis-Filho JS. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008; 215:398-410. [PMID: 18484683 DOI: 10.1002/path.2368] [Citation(s) in RCA: 124] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Pure invasive micropapillary carcinoma (MPC) is a special histological type that accounts for 0.7-3% of all breast cancers. MPC has a distinctive growth pattern and a more aggressive clinical behaviour than invasive ductal carcinomas of no special type (IDC-NSTs). To define the molecular characteristics of MPCs, we profiled a series of 12 MPCs and 24 grade and oestrogen receptor (ER)-matched IDC-NSTs using high-resolution microarray comparative genomic hybridization (aCGH). In addition, we generated a tissue microarray containing a series of 24 MPCs and performed immunohistochemical analysis with ER, PR, Ki-67, HER2, CK5/6, CK14, CK17, EGFR, topoisomerase-IIalpha, cyclin D1, caveolin-1, E-cadherin, and beta-catenin antibodies. In situ hybridization probes were employed to evaluate the prevalence of amplification of HER2, TOP2A, EGFR, CCND1, MYC, ESR1, and FGFR1 genes. aCGH analysis demonstrated that MPCs significantly differed from IDC-NSTs at the genomic level. Gains of 1q, 2q, 4p, 6p, 6q23.2-q27, 7p, 7q, 8p, 8q, 9p, 10p, 11q, 12p, 12q, 16p, 17p, 17q, 19p, 20p, 20q, and 21q, and losses of 1p, 2p, 6q11.1-q16.3, 6q21-q22.1, 9p, 11p, 15q, and 19q were more prevalent in MPCs. High-level gains/amplifications of 8p12-p11, 8q12, 8q13, 8q21, 8q23, 8q24, 17q21, 17q23, and 20q13 were significantly associated with MPCs. A comparison between 24 MPCs and a series of 48 grade and ER-matched IDC-NSTs revealed that high cyclin D1 expression, high proliferation rates, and MYC (8q24) amplification were significantly associated with MPCs. Our results demonstrate that MPCs have distinct histological features and molecular genetic profiles supporting the contention that they constitute a distinct pathological entity.
Collapse
Affiliation(s)
- C Marchiò
- The Breakthrough Breast Cancer Research Centre--Institute of Cancer Research, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Scheller D, Schmidt W, Jackson M, Ruess U, Stockwell K, Heindl M, Iravani M, Tayarani-Binazir K, Rose S, Jenner P. Kontinuierliche versus pulsatile Applikation von Rotigotin in einem Ratten- und Affen-Modell der Parkinsonkrankheit: ein Vergleich. Akt Neurol 2008. [DOI: 10.1055/s-0028-1086785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Simpson PT, Reis-Filho JS, Lambros MBK, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Dexter T, Jones A, Reid L, Da Silva L, Shin SJ, Hardisson D, Ashworth A, Schmitt FC, Palacios J, Lakhani SR. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008; 215:231-44. [DOI: 10.1002/path.2358] [Citation(s) in RCA: 128] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
31
|
Ghavamzadeh A, Alimoghaddam K, Ghaffari S, Rostami S, Jahani M, Iravani M, Hosseini R, Khodabandeh A, Mousavi S, Eini E. 6017 POSTER First line treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and chemotherapy. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71308-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
32
|
Ghavamzadeh A, Alimoghaddam K, Ghaffari S, Rostami S, Jahani M, Khodabandeh A, Mossavi S, Iravani M, Eini E, Moghadam Z, Afshar F. First-line treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and chemotherapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7073 Background: Standard treatment of APL is ATRA plus chemotherapy but Arsenic Trioxide (ATO) is most potent single agent against APL cells. Role of ATO in first line therapy of APL needs to clarify. Methods: Between may 2000 and September 2006,we treated 141 new cases of APL(Median age 28±12.8 y/o min=11,max=71) by 2 hours iv infusion of 0.15mg/kg ATO until complete remission. Trial approved by IRB and consent form obtained. Diagnosis was by clinical and morphologic characteristics and confirmed by cytogenetic and RT-PCR for detection of t(15,17) and presence of PML-RARa. After complete remission patients received consolidation by 28 days infusion of ATO for one or four courses.(one consolidation one month after CR and for some patients second, third and forth consolidations one month after first one and two another , one year and two year after CR) Results: : complete remission observed in 121 cases(85.8%) and early mortality rate was14.9%(most common cause of early mortality was APL syndrome,61.9%).Median follow up was 28 months. For patients who achieve to complete remission,one, two and three year disease free survival were 95.6%± 2%, 76.9±4% and 57± 6%,respectively. Many relapsed patients salvaged again with ATO alone so, two and three years overall survival for this cohort was 95.6%±2% and 83.7%±4%. Increasing number of consolidation from one to four couldn’t increase DFS or OS in one and two years after CR. Conclusions: ATO is effective in treatment of new cases of APL. Introduction of ATO in first line treatment of APL(with or without ATRA plus chemotherapy) needs a multi center randomized clinical trial. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Ghavamzadeh
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - K. Alimoghaddam
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - S. Ghaffari
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - S. Rostami
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - M. Jahani
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - A. Khodabandeh
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - S. Mossavi
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - M. Iravani
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - E. Eini
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - Z. Moghadam
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| | - F. Afshar
- Hematology, Oncology and BMT Research Center, Tehran, Islamic Republic of Iran
| |
Collapse
|
33
|
Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, Samiee S, Chahardovali B, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transplant 2007; 40:105-10. [PMID: 17468775 DOI: 10.1038/sj.bmt.1705685] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Busulfan and cyclophosphamide (BuCy) are currently the most widely used myeloablative regimen to treat malignancies with allogeneic stem cell transplantation. Fludarabine has considerable efficacy in both immunosuppression and tumor cells killing with a minimal extramedullary toxicity. We evaluated the efficacy of 40 mg/m(2) fludarabine i.v. for 5 days and busulfan 4 mg/kg/day p.o. for 4 days as myeloablative conditioning regimen in 70 patients (median age 24 years) with acute leukemia or chronic phase of myelogenous leukemia. They all had human leukocyte antigen-matched sibling donors. The patients received 10 mug/kg granulocyte colony stimulating factor (GCSF), 24 h after stem cell infusion until engraftment occurred. Graft-versus-host disease (GVHD) prophylaxis included 3 mg/kg cyclosporine-A i.v. from day -2 to +6 followed by 12 mg/kg p.o. until day +60. The median time of neutrophil recovery (>0.5 x 109/l) and platelet recovery (>20 x 109/l) were 10 and 12 days, respectively. Mucositis (93%) and hepatic toxicity (16%) resolved with conservative therapy. The incidence of acute GVHD grade I-II and III-IV were 38.6 and 15.7% respectively. Overall survival and disease-free survival were 71 and 64% respectively with 17 months median follow-up for surviving patients. We conclude that FluBu may be used as a substitute for BuCy with almost the same efficacy and with a lower transplant adverse effect but to increase anti-leukemic effects, especially in acute lymphoblastic leukemia patients, it needs some modifications.
Collapse
Affiliation(s)
- M Iravani
- Hematology-Oncology and BMT Research Center, Medical Sciences, University of Tehran, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Gavamzadeh A, Ali Mogaddam K, Nedaeifard L, Jahani M, Mousavi A, Iravani M, Bahar B, Khodabandelu. 129: 15 years hematopoietic stem cell transplantation for beta Thalassemia Major in Tehran. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2006.12.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Iravani M, Ali Mogaddam K, Nedaeifard L, Khatami F, Gavamzadeh A, Golibeygian S, Bab Hadiashar N, Jalili M, Tagipur R, Gaffari F, Mousavi A. 246: Allogeneic blood and marrow transplantation in thalassemia major class 3. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2006.12.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Ghavamzadeh A, Samiee S, Mahdavi N, Bakhti O, Jahani M, Alimoghaddam K, Iravani M, Bahar B, Khodabandeh A, Mousavi A. 130: The incidence of secondary malignancy after stem cell transplantation, the importance of total body irradiation. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2006.12.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Pierga JY, Reis-Filho JS, Cleator SJ, Dexter T, MacKay A, Simpson P, Fenwick K, Iravani M, Salter J, Hills M, Jones C, Ashworth A, Smith IE, Powles T, Dowsett M. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 2007; 96:341-51. [PMID: 17133270 PMCID: PMC2359992 DOI: 10.1038/sj.bjc.6603483] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 10/12/2006] [Accepted: 10/23/2006] [Indexed: 12/29/2022] Open
Abstract
We analysed the molecular genetic profiles of breast cancer samples before and after neoadjuvant chemotherapy with combination doxorubicin and cyclophosphamide (AC). DNA was obtained from microdissected frozen breast core biopsies from 44 patients before chemotherapy. Additional samples were obtained before the second course of chemotherapy (D21) and after the completion of the treatment (surgical specimens) in 17 and 21 patients, respectively. Microarray-based comparative genome hybridisation was performed using a platform containing approximately 5800 bacterial artificial chromosome clones (genome-wide resolution: 0.9 Mb). Analysis of the 44 pretreatment biopsies revealed that losses of 4p, 4q, 5q, 12q13.11-12q13.12, 17p11.2 and 17q11.2; and gains of 1p, 2p, 7q, 9p, 11q, 19p and 19q were significantly associated with oestrogen receptor negativity. 16q21-q22.1 losses were associated with lobular and 8q24 gains with ductal types. Losses of 5q33.3-q4 and 18p11.31 and gains of 6p25.1-p25.2 and Xp11.4 were associated with HER2 amplification. No correlations between DNA copy number changes and clinical response to AC were found. Microarray-based comparative genome hybridisation analysis of matched pretreatment and D21 biopsies failed to identify statistically significant differences, whereas a comparison between matched pretreatment and surgical samples revealed a statistically significant acquired copy number gain on 11p15.2-11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages.
Collapse
Affiliation(s)
- J-Y Pierga
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
- Medical Oncology Department, Institut Curie, Paris, cedex 5, France
| | - J S Reis-Filho
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - S J Cleator
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - T Dexter
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - A MacKay
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - P Simpson
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - K Fenwick
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - M Iravani
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - J Salter
- Academic Department of Biochemistry, Royal Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ, UK
| | - M Hills
- Academic Department of Biochemistry, Royal Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ, UK
| | - C Jones
- Section of Paediatric Oncology, Institute of Cancer Research, London, SM2 5NG, UK
| | - A Ashworth
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - I E Smith
- Breast Cancer Unit, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - T Powles
- Breast Cancer Unit, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - M Dowsett
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
- Academic Department of Biochemistry, Royal Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ, UK
| |
Collapse
|
38
|
Shaiegan M, Hadjati E, Aghaiipour M, Iravani M, David G, Bernard D. Flow cytometric evaluation of red blood cell chimerism after bone marrow transplantation in Iranian patients: a preliminary study. Arch Iran Med 2006; 9:406-9. [PMID: 17061616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The aim of this study was to evaluate mixed red cells population and red blood cell chimerism after hematopoietic stem cell transplantation. Red blood cell chimerism after hematopoietic stem cell transplantation was analyzed using a series of fluorescein isothiocyanate-conjugated monoclonal antibodies (BioAtlantic, France) directed against ABH, Rh (D, C, E, c, e), Kell, Duffy, Kidd, and Ss antigens on blood samples of 14 patients with hematologic disorders undergoing hematopoietic stem cell transplantation, by flow cytometric method on days 15, 30, and 60 after transplantation. All patients showed expression of donor red cell antigens within days 15 - 30 after hematopoietic stem cell transplantation. Graft versus host disease and ABO incompatibility did not affect the expression of chimerism. Flow cytometric analysis is a simple, accurate, and valuable test which is of significant help in monitoring chimerism in allogeneic hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- Mojgan Shaiegan
- Department of Immunology, Iranian Blood Transfusion Organization Research Center (IBTORC), Tehran, Iran.
| | | | | | | | | | | |
Collapse
|
39
|
Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006; 210:49-58. [PMID: 16823893 DOI: 10.1002/path.2021] [Citation(s) in RCA: 97] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Despite the excellent survival of Wilms tumour patients treated with multimodality therapy, approximately 15% will suffer from tumour relapse, where response rates are markedly reduced. We have carried out microarray-based comparative genomic hybridisation on a series of 76 Wilms tumour samples, enriched for cases which recurred, to identify changes in DNA copy number associated with clinical outcome. Using 1Mb-spaced genome-wide BAC arrays, the most significantly different genomic changes between favourable histology tumours that did (n = 37), and did not (n = 39), subsequently relapse were gains on 1q, and novel deletions at 12q24 and 18q21. Further relapse-associated loci included losses at 1q32.1, 2q36.3-2q37.1, and gain at 13q31. 1q gains correlated strongly with loss of 1p and/or 16q. In 3 of 11 cases with concurrent 1p(-)/1q(+), a breakpoint was identified at 1p13. Multiple low-level sub-megabase gains along the length of 1q were identified using chromosome 1 tiling-path arrays. One such recurrent region at 1q22-q23.1 included candidate genes RAB25, NES, CRABP2, HDGF and NTRK1, which were screened for mRNA expression using quantitative RT-PCR. These data provide a high-resolution catalogue of genomic copy number changes in relapsing favourable histology Wilms tumours.
Collapse
MESH Headings
- Chromosome Aberrations
- Chromosome Deletion
- Chromosomes, Human, Pair 1/genetics
- Chromosomes, Human, Pair 16/genetics
- Chromosomes, Human, Pair 8/genetics
- DNA, Neoplasm/genetics
- Genes, Wilms Tumor/physiology
- Humans
- Kidney Neoplasms/genetics
- Kidney Neoplasms/pathology
- Neoplasm Recurrence, Local/genetics
- Oligonucleotide Array Sequence Analysis/methods
- RNA, Messenger/analysis
- RNA, Neoplasm/analysis
- Treatment Outcome
- Wilms Tumor/genetics
- Wilms Tumor/pathology
Collapse
Affiliation(s)
- R Natrajan
- Paediatric Oncology, Institute of Cancer Research/Royal Marsden NHS Trust, Sutton, Surrey SM2 5NG, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Alimoghaddam K, Ghaffari H, Foroughi F, Chardouli B, Sanaat Z, Bahar B, Mousavi A, Iravani M, Ghavamzadeh A. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran. Arch Iran Med 2006; 9:99-103. [PMID: 16649348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
BACKGROUND The coexistence of recipient's and donor's hematopoietic systems after allogeneic marrow transplantation is called mixed chimerism. OBJECTIVE The objective of this study was to evaluate the effects of MC on graft-versus-host disease (GVHD), disease recurrence, and survival after HLA identical marrow transplantation in a transplant center in Iran. METHODS The association of MC with acute GVHD, disease recurrence, survival, and relapse-free survival was investigated in 91 patients who underwent either bone (n = 12) or peripheral blood (n = 79) HLA-identical marrow transplantation. Chimerism was assessed using multiplex amplification of short tandem repeats (STR). Patients had thalassemia (n = 19), acute myelogenous leukemia (AML) (n = 29), acute lymphocytic leukemia (ALL) (n = 20), chronic myelogenous leukemia (CML) (n = 18), and other diseases (n = 5). The median age was 21 (range: 3 - 50) years. There were 38 (42%) female and 53 (58%) male participants. Conditioning was made through busulfan plus cyclophosphamide in 34 patients; busulfan plus fludarabin in 51 patients; and busulfan plus fludarabin plus antithymocyte globulin in 6 patients. The median follow-up was 13 months. RESULTS On day +30, complete chimerism (CC) was observed in 72 (79%) patients, MC in 15 (17%), and no chimerism in 4 patients. The incidence of acute GVHD was significantly (P = 0.01) lower in mixed chimeras than in complete chimeras. There was no significant difference in acute GVHD grade (I, II vs. III, IV) between the two groups. The incidence of relapse was 18%. There was no difference in relapse rate between MC and CC groups. Overall survival was 89%. There was no significant difference in the overall survival between MC and CC group (96% vs. 85%, respectively). Relapse-free survival was 80% that was not significantly different between the two groups. CONCLUSION Despite some previous reports, we found no significant difference in the survival and relapse rates between MC and CC groups.
Collapse
MESH Headings
- Adolescent
- Adult
- Bone Marrow Transplantation/immunology
- Child
- Child, Preschool
- Chimera/immunology
- Female
- Graft Rejection/epidemiology
- Graft vs Host Disease/epidemiology
- Graft vs Host Disease/immunology
- HLA Antigens/immunology
- Humans
- Iran
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/mortality
- Male
- Middle Aged
- Minisatellite Repeats
- Polymerase Chain Reaction
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality
- Recurrence
- Survival Analysis
- Thalassemia/immunology
- Thalassemia/mortality
- Transplantation Conditioning
- Transplantation, Homologous
Collapse
Affiliation(s)
- Kamran Alimoghaddam
- Hematology-Oncology and BMT Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Iravani M, Nedaeifard L, Alimoghaddam K, Mousavi A, Karimi M, Ghavamzadeh A. Bone marrow transplantation in a child with type C of niemann-pick disease (second case in the world). Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
42
|
Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, Eghbal L, Ghavamzadeh A. Cyclosporin A and mini short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
43
|
Iravani M, Nedaeifard L, Arshy M, Toutounchi M, Ghavamzadeh A. Early hepatic complication in first year after bone marrow transplantation in major βthalassemia patients. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
44
|
Esfahani A, Iravani M, Khoushniat M, Ghoreishi Z, Shamshiri A, Ghavamzadeh A. Assesment of bone loss after bone marrow transplantation in patients with leukemia and lymphoma. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Armistead P, Mohseni M, Gerwin R, Iravani M, Ghavamzadeh A, Ritz J, Wu C. Post-transplant monitoring of erythroid lineage specific chimerism. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Brookman-Amissah N, Duchesnes C, Williamson MP, Wang Q, Ahmed A, Feneley MR, Mackay A, Freeman A, Fenwick K, Iravani M, Weber B, Ashworth A, Masters JR. Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH. Prostate Cancer Prostatic Dis 2006; 8:335-43. [PMID: 16130014 DOI: 10.1038/sj.pcan.4500826] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Copy number alterations in a matched pair of benign epithelial and prostate cancer cell lines derived from the same patient were assessed using array-based comparative genomic hybridisation (aCGH). The cancer cell line showed a gain of chromosome 7, deletion of chromosome 8, gains (including high level) and losses on chromosome 11, loss of 18p and gain of 20q. Deletions on chromosome 8 were confirmed with microsatellite markers. The aCGH results were compared to gene expression data obtained using DNA microarrays and suggested the involvement of caspases and ICEBERG on 11q and E2F1 on chromosome 20q.
Collapse
Affiliation(s)
- N Brookman-Amissah
- Prostate Cancer Research Centre, Institute of Urology, University College London, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17:131-4. [PMID: 16227315 DOI: 10.1093/annonc/mdj019] [Citation(s) in RCA: 146] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
INTRODUCTION Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear. MATERIALS AND METHODS We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT-PCR) on peripheral blood samples. RESULTS Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1-57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically. CONCLUSIONS Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.
Collapse
Affiliation(s)
- A Ghavamzadeh
- Haematology, Oncology and BMT Research Centre, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol 2005; 15:223-7. [PMID: 16431290 DOI: 10.1016/j.trim.2005.10.002] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2005] [Revised: 09/28/2005] [Accepted: 10/24/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND Graft-versus-host disease is one of the major complications after allogeneic bone marrow transplantation, but it is not easy to anticipate the onset. Cytokines released by type 1 T helper cells are thought to play a pivotal role in acute graft-versus-host disease aGVHD. The ability to predict the likely occurrence of graft-versus-host-disease (GVHD) after Hematopoietic Stem cell Transplantation (HSCT) would be extremely valuable. By serially measuring serum levels of soluble IL-2 receptor (sIL-2R), IL-18 and following allogeneic HSCT we tried to define their effect on aGVHD as a complication of transplantation and determine useful markers for aGVHD predictors. SAMPLES AND METHODS Serum sIL-2R, IL-18, levels were measured by sandwich ELISA in 219 sera samples from 39 patients (with hematological disorders before and after allogeneic HSCT) and 28 controls. All patients received transplants from HLA-identical siblings. RESULTS 23 (58.9%) patients developed aGVHD (I-IV) and serum levels of sIL-2R and IL-18, in sera drawn before transplantation, in patients with acute graft-versus-host disease (aGVHD(+)), were increased in comparison to patients without acute graft-versus-host disease (aGVHD(-)) and to a control group and there were no significant differences in serum levels of sIL-2R and IL-18 in aGVHD(-) patients and controls. Serum level of IL-18, in aGVHD(+) patients, was increased during days 3-24 after HSCT, and there was a significant difference according to GVHD severity. In majority of patients with acute GVHD (60%), the peak levels of IL-18 and sIL-2R were achieved on day 10 after HSCT and the rise in sIL-2R and IL-18 preceded the clinical signs of GVHD (mean day 15 after BMT). The level of IL-18 in patients with aGVHD strongly correlated with the severity of aGVHD on Day 10 after HSCT. IL-18 level (before HSCT), in patients who received Busulfan and Fludarabin which were used to treat aGVHD, was lower than in patients who received Busulfan and Cyclophosphamide. CONCLUSION Our data concluded that IL-18 plays an important role in the development of aGVHD and the IL-18 level might be an indicator of aGVHD, reflecting the severity of the disease. These findings suggest that IL-18 may play an important role in the pathogenesis of aGVHD and that measurement of serum IL-18 levels can be a useful indicator of aGVHD.
Collapse
Affiliation(s)
- Mojgan Shaiegan
- Immunology Lab. Iranian Blood Transfusion Organization Research Center, Hemmat highway, Tehran, Iran.
| | | | | | | |
Collapse
|
49
|
Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, Eghbal L, Ghavamzadeh A. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant 2005; 35:1095-9. [PMID: 15821773 DOI: 10.1038/sj.bmt.1704935] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We compared the effects of cyclosporin A (CsA) alone as graft-versus-host disease (GVHD) prophylaxis vs cyclosporine with short-course methotrexate (MTX) in patients with thalassemia. In all, 140 patients were enrolled in this study. The first group, of 50 patients, received CsA alone at 3 mg/kg i.v. from day -2 to +5 followed by 12.5 mg/kg p.o., which was tapered according to the patient's condition. The other group, of 90 patients, received the combination of CsA+MTX in which CsA was used with the above-mentioned dose and MTX was on 10 mg/m(2) day +1 and 6 mg/m(2) on days +3 and +6. Incidence of acute GVHD grade II-IV in the CsA group was 78% and in the CsA+MTX group was 52.2%, which was statistically significant (P=<0.001). There were no significant differences in the incidence of chronic GVHD between the two groups. The mean neutrophil engraftment to 0.5 x 10(9)/l was 14 and 23 days for CsA group and CsA+MTX group, respectively (P=<0.001). There were no significant differences for platelet recovery between the two groups. Graft failure in the CsA and CsA+MTX groups was seven (14%) and nine (10%) patients, respectively (P=0.58). Overall survival in the CsA and CsA+MTX groups was 77 and 85%, respectively. Disease-free survival in the CsA and CsA+MTX groups were 58 and 80%, respectively.
Collapse
Affiliation(s)
- M Iravani
- Hematology-Oncology & BMT Research Center, Tehran University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Iravani M, Tavakoli M, Shamshiri A, Mousavi A, Bahar B, Jahani M, Ghavamzadeh A. Myeloablative conditioning with fludarabine and busulfan for allogeneic PBSCT in chronic phase CML. Biol Blood Marrow Transplant 2005. [DOI: 10.1016/j.bbmt.2004.12.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|